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1. INTRODUCTION 
The incidence of different types of leukemia varies with age 
through out the world.1 In India, Parkienstal et al reported that 
leukemias are the most common cancer affecting the children 
accounting for 25 – 35% of malignancies.2 The majority of them were 
ALL and most were in age groups 0 – 3 yrs, 4 – 6 yrs and 7 – 9 yrs. 
ALL is most frequent in South India3. In Chennai, leukemia was 
reported as the highest among the first five childhood cancers.1 
Acute leukemia is a malignancy arising due to the clonal 
proliferation of abnormal hematopoietic cells leading to disruption of 
normal marrow function resulting in increased number of blast cells  
> 20% (Normally blast cells <5%).4 
Patients with acute leukemia undergoing induction chemotherapy 
have prolonged thrombocytopenia, because of the cytotoxic therapies 
they receive and also of their underlying disorder. Bleeding is a frequent 
complication in leukemic children even after prophylactic or therapeutic 
platelet transfusion.5 
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 Valleri et al suggested that transfusion of RBC to anemic 
thrombocytopenic patients would be effective before transfusing viable 
platelets.  Maintenance of hemoglobin concentration of a patient with 
thrombocytopenia at higher levels may contribute to improve 
hemostasis.6 
In tertiary care centres, platelet transfusions are widely used for 
the management of bleeding in thrombocytopenic leukemic patients.7 
Clinicians faced with an abnormal laboratory value may use transfusion 
therapy to correct the value rather than to achieve a clinical result.8 
Prophylactic transfusion may or may not improve platelet survival when 
compared to transfusion in response to active bleeding.5 
A reliable platelet count and appropriate clinical evaluation of the 
leukemic patients showed that a significantly lower threshold is needed 
more for therapeutic transfusion than for prophylactic transfusion.9 
For the past 30 years platelet transfusion have been used in the 
treatment of thrombocytopenia caused by decreased production, 
inadequate function or increased destruction of platelets. The number  
of platelet transfusion has increased in leukemic patients due to 
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aggressive chemotherapies producing more acute and prolonged 
thrombocytopenia.10 So the present study was undertaken to find the 
 
(i) need for transfusion in leukemic children and 
(ii) to evaluate the effectiveness of RBC and platelet 
transfusion for them.  
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2. AIMS AND OBJECTIVES 
(i) To study the need for  transfusion in leukemic children. 
(ii) To identify the blood component most commonly used for 
transfusion. 
(iii) To find the pre and post Hemoglobin estimation. 
(iv) To find the pre and post platelet count increment. 
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3. REVIEW OF LITERATURE 
3.1 Methods of component preparation 
Platelet rich plasma (PRP) can be separated from whole blood by 
a soft centrifugation. The processing of blood and PRP are done at room 
temperature (22°C) and holding the sedimented platelets stationary for 
30 – 60 minutes before resuspending them as platelet concentrates 
(PC).11 Platelet rich plasma was the first method used to prepare PC12. 
Platelet concentrates from Whole blood are often referred to as “random 
donor platelets”. Platelet concentrates are prepared by centrifugation of 
standard amounts of whole blood.13 Preparation of platelet concentrates 
are done from anti coagulated whole blood by the “platelet rich plasma” 
and or “buffy coat techniques”.11 
There are two methods for doing platelet preparation  
(i) Platelet rich plasma (PRP) method. 
(ii) Buffy coat (BC) Method.  
In the PRP method, an initial Low G force (soft) spin produces 
PRP, which is then separated from the packed red cells. PRP is then 
centrifuged at a higher G force (hard) spin and the supernatant platelet 
poor plasma is removed. The residual PC contain approximately 0.5 to 
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0.75 x1011 platelets / unit or approximately 60to 75% of the platelets 
from the original unit of blood.13 One draw back is that this method 
results in 108 WBC or approximately 50% or more Leukocyte 
contamination occurs during seperation from the original unit of Whole 
Blood.13 
In the second method i.e. Buffy coat method, anticoagulated 
whole blood is subjected to hard spin, resulting in separation of platelet 
poor plasma (supernatant), buffy coat (intermediate) and PRBC at the 
bottom. Buffy coat is separated and subjected to soft spin leading to 
separation of PRP and WBC with residuals. 
Platelet Rich Plasma Preparation 
  
 
 
 
 
 
Anti coagulated whole 
blood 
PRBC Platelet Rich 
Plasma 
Soft Centrifugation 
Hard Centrifugation 
Platelet poor 
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Platelet 
Concentrate 
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Buffy coat preparation 
 
 
 
 
 
3.2 Storage 
Platelets are stored at 20˚C to 24˚C using continuous gentle 
horizontal agitation in storage bags specifically designed to permit 
Oxygen and Carbon dioxide exchange to optimize platelet quality.13 
This combination of storage bag, constant agitation preservative 
solution, temperature and the use of approximately 50 ml of plasma 
permit satisfactory preservation of platelets up to 5 days.  
3.3 Transfusion 
Platelet storage also has an impact on platelet transfusion 
efficacy. Transfusion with platelets stored from day 0 to day 5 were 
Anti coagulated whole 
blood 
Plasma PRBC Buffy 
Coat 
Soft Centrifugation 
Platelet 
Concentrate 
WBC & 
Residual 
Hard  Centrifugation 
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used14. All the platelets used were ABO group identical between Donor 
and the recipient. A single  unit transfusion was considered as one 
transfusion episode and is defined as either RBC unit or unit of “whole 
blood derived platelet concentrate”.14  
3.4 Hematology Analyzer 
In blood banks hematology analyzers, are used to count cells in 
blood products. These blood products are derived from centrifuged 
whole blood.15 Platelet counting in platelet concentrates should be 
validated separately for platelet collected from whole blood because 
most of the analyzers are designed to count platelets in the presence of 
RBC. Platelet counting in the absence of RBC might result in deviating 
from correct platelet counts. The samples were taken in a EDTA tube. 
Significantly higher platelet count in the EDTA tube was observed by 
the cell analyzer than in the dry tube.15  
3.5 Role of RBCs in bleeding 
Intensive therapies which produce severe and sustained 
thrombocytopenia are used routinely in patients with hematological 
malignancies.13 Guidelines for transfusion exist, but variability in their 
application, particularly in children, remains as a big concern.1 Non 
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surgical blood loss refers to generalized, systemic bleeding that is not 
corrected by surgical interventions. A correlation exists between anemia 
and prolonged bleeding time. When the anemia is corrected, the 
bleeding time is reduced. Platelet function is known to be a major 
determinant of bleeding time and anemia produces a reversible platelet 
dysfunction.6  
RBCs show beneficial effect on platelet function by dispersing 
platelets from the centre of the blood vessel towards the vessel wall, 
RBCs concentrate platelets near the endothelial cells of the blood vessel, 
where they are balanced to respond to injury.6 Haemostatic effect of 
RBC is to scavenge endothelial cell and nitric oxide, a vasodilating 
agent that inhibits platelet function. In addition, Endothelin, a potent 
vasoconstrictor substance may be released from endothelial cells. RBCs, 
like platelets at the bleeding site may provide arachidonic acid and 
adenosine di-phosphate to stimulate the platelets to release 
thromboxane, another potent vasoconstrictor substance and a platelet 
aggregating substance.6 At the bleeding site, the platelets and RBC’s are 
activated and phosphatidyl serine is exposed on both the platelets and 
RBC’s. Factor Va and Factor Xa activates prothrombinase to produce 
thrombin, which accumulates on the platelets and RBCs.6 
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A Hematocrit level of 35 volume percent at the site of bleeding 
minimizes shear stress and reduces nitric oxide produced by endothelial 
cells.16 Therefore trigger for prophylactic platelet transfusion should 
consider both the Hematocrit and the platelet count. If WBC depleted 
platelets are used, it will modify the development of allo immunisation 
in leukemia.17 
Pooled platelet products and single donor apheresis platelet 
concentrates are considered to be equally effective and safe.18  
A standard dose of 0.5 x 1011  platelets per 10 kg for platelet transfusion 
is generally accepted.18 Children who need blood transfusion receive a 
calculated volume of blood depending on their weight, instead of whole 
number of units.19 Acute Leukemic children during therapy receive on 
an average 80 – 110 units of platelets and 20 – 40 units of red cells.20 
There should be documentation on the patients chart indicating whether 
the patient had a chance to discuss about the need for blood transfusion 
and its procedure. The documentation has considerable importance in 
terms of recognizing a delayed transfusion reaction or a transfusion 
transmitted diseases.15 Clinical Judgment is the principal factor in 
determining whether a RBC transfusion is indicated. The benefits of the 
hematocrit range of 30 to 35 percent includes improved Oxygen delivery 
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and enhanced hemostasis.6 Haemoglobin level increase is always 
associated with the transfusion of red cells in anemic cancer patients. 
3.6 Clinical features  
In leukemia, the blast cells replace normal hematopoietic cells in 
the marrow resulting in Anemia, thrombocytopenia and neutropenia. 
Most of the clinical symptoms are due to anemia, neutropenia and 
thrombocytopenia.21 
The most common presenting clinical features of leukemia are :  
1. Fatigue and pallor 
2. Respiratory infection – Brochopnemonia  
3. Bone pain – sternal tenderness 
4. Lymphadenopathy  
5. Hepatosplenomegaly 
6. CNS involvement and 
7. Petechial hemorrhages and mucosal bleeds 
3.7 Hematological findings in Leukemia 
The presence of blast cells in Blood and Bone marrow with 
reduction of normal hematopoietic cells is the hall mark of leukemia. 
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Peripheral smear reveals blast cells which vary from as few as 1% to as 
high as 98 – 99% .Blast cells are either lymphoblasts in ALL or 
myeloblasts in AML. Lymphoblast may be of L1 L2 or L3 morphology 
and demonstrate block positivity with Periodic Acid Schiff stain. 
Myeloblasts are positive for Sudan Black and Myeloperoxidase B stains. 
3.8 Bleeding in Leukemic Children 
In leukemic children, skin bleeding (Petechiae) is a sufficient 
clinical sign to transfuse platelets.22  The other common clinical 
indicators for therapeutic platelet transfusion are gastrointestinal, 
genitourinary (Hematuria) and retinal hemorrhages. Significant bleeding 
included all bleeding except petechiae formation in dependant areas, 
ecchymoses not larger than 1 cm in diameter and/or more than 5 in 
number or oozing of blood from the periodontal groove.23  
3.9 Categorization of bleeding events 
The bleeding event is categorized as no bleeding, non clinically 
significant bleeding and clinically significant bleeding and the 
corresponding WHO grade and symptoms are mentioned below.9,6 
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Table 1 Categorization of bleeding events 
Bleeding 
Category 
Corresponding 
WHO Grade 
Description of bleeding 
Signs / Symptoms 
No bleeding  0 No bleeding 
Non clinically 
significant  
Bleeding               
1 1. Petechiae 
2. Purpura 
3. Mucocutaneous 
hemorrhage 
4. Mild vaginal spotting 
5. Mildhemorrhoidal spotting 
6. Oropharyngeal bleeding 
7. Epistaxis not requiring 
Packing or intervention 
8. Retinal hemorrhage without 
visual impairment 
9. Hematomas not requiring 
red cell transfusion 
Clinically  
significant 
bleeding   
2, 3 or 4 1. Malena 
2. Hematomas 
3. Hemoptysis whether or not 
blood Transfusions where 
required (WHO> 2) 
4. Hematuria 
5. Hematochezia 
6. Abnormal vaginal bleeding 
7. Epistaxis requiring package 
or intervention 
8. Bleeding from invasive 
sites 
9. Musculoskeletal bleeding 
10. Hematoma (soft tissue 
bleeding) 
11. Body  cavity fluids reported 
as grossly bloody 
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3.10 Role of platelets in bleeding 
The life span of platelets is dependent on a patient’s platelet 
count. Although a platelet survives approximately nine days in a normal 
individual, platelets have a reduced survival in thrombocytopenic 
patients. The residual mean life span corresponds to the maximal 
expected life span of a donated platelet product after infusion into the 
patient. The explanation offered for these observed differences is that 
the platelets are removed from the circulation by two mechanisms. First 
is simply platelet senescence which accounts for majority of platelet loss 
in normal individual and the second is a constant loss due to the routine 
maintenance of vascular integrity (an endothelial supportive role). The 
number of platelets required for this endothelial supportive role has been 
estimated to be 7.1 x 103/µl/day. It is thought that in thrombocytopenic 
patients the constant loss for haemostatic maintenance represents a more 
significant fraction of the circulating platelets, thus reducing platelet 
survival9.Certain clinical factors also influence the in vivo survival of 
activated platelets which may be the major cause of refractoriness to 
platelet transfusion.10,24 
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3.11 Prophylactic platelet transfusion 
Prophylactic platelet transfusion is an important part of supportive 
care measures in modern treatment. The aim of prophylactic transfusion 
is the prevention of major as well as minor bleedings during the time of 
disease or therapy induced thrombocytopenia.18 Hospitals have tried to 
reduce platelet use and the cost of platelet transfusion by transfusing 
platelets at lower platelet counts more frequently. But it is not optimal 
for cancer patients receiving intensive chemotherapy who require 
multiple platelet transfusion.10 There are studies determining the optimal 
transfusion trigger for prophylactic platelet transfusions in patients who 
have chemotherapy induced thrombocytopenia. Most of the centers now 
use a trigger of 10x109/L to transfuse platelet products.25  
More than 70 percent of hospitals reported transfusing platelets 
primarily for prophylaxis.  60 percent of the hospitals set the threshold 
platelet count for prophylactic platelet transfusion at 20,000/µl. A 
platelet count of 50,000/µl was most frequently required for 
performance of a minor invasive procedure. Finally the authors 
concluded that there is a considerable variation in platelet transfusion 
practice. For pediatric patients, in particular, the dose of platelets 
transfused was individualized on the basis of the weight of the child. 
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Among 20% of institutions surveyed reported that, among clinicians, the 
most common reason for platelet transfusions was for hemostasis in 
response to active bleeding.20  
Recent studies suggest that the threshold for prophylactic platelet 
transfusion may be safely lowered to 10x109 / L from previous standards 
of  20x109/ L Earlier studies of spontaneous bleeding demonstrated that  
bleeding risk increased dramatically only at platelet counts below 5x109 
litre.26 In current practice, most platelet transfusion is given for 
prophylaxis. one random unit/10 kg for pediatric patients is the usual 
dose. Platelet survival varies with platelet count because of consumption 
of a fixed number of platelets each day to maintain vascular integrity. If 
prophylactic transfusion for severe thrombocytopenia are intended to 
maintain vascular integrity, then the total platelet usage may be 
determined by that fixed consumption, rather than by senescence of 
excess transfused platelets.26 
73% of the platelet transfusions that were given to the patients 
occurred with pre transfusion counts of more than 10x109/L which is the 
pre transfusion count trigger for prophylactic platelet transfusion that is 
now generally accepted in the literature. This mean next day increment 
for all transfusion, 10.2 x 10 9 / L is much lower than the 30x109/L that 
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is often cited as the rule of thumb for the expected increase in 
uncomplicated patients.5 
Clinical trials have shown that one hour post transfusion count is 
a good measure of response to transfusion whereas the 24 hour count 
can be used to monitor platelets survival. Astler and Jandl showed that 
the recovery of platelets when labeled and re-infused into an autologous 
normal donor is not 100 percent but rather 52 percent. The decreased 
recovery is attributed to pooling of normal platelets in the spleen. This 
pooling is not reversible as platelets go back and forth between the 
spleen and the general circulation. On an average, one platelet is in the 
spleen for two in the circulation.27 A fixed number of platelets is 
required for hemostasis each day. As thrombocytopenia worsens, the 
percentage of platelets used each day increases. So the choice of  
50 percent for mean cell life (MCL) was based on physiological and 
medical considerations.27 
Some institutions did not use any specific platelet count for 
prophylactic transfusion, because the patient’s clinical condition played 
an important role in the decision to transfuse. It is inappropriate to 
automatically administer the platelet transfusion at a given platelet count 
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and that the number of platelet transfusion administered to many 
patients can be decreased with proper clinical evaluation.20 
3.12 Group matched platelets 
It has been an accepted practice for platelets to be transfused out 
of ABO group as a second line therapy when ABO matched platelets are 
unavailable. The mismatch is tolerated in most cases owing to the 
assumption that the antibodies and volume of incompatible plasma 
transfused will be diluted in the total blood volume of the recipient. This 
dilution prevents passively acquired ABO antibodies from causing a 
clinically significant problems.27 Intravascular hemolysis secondary to 
minor ABO mismatch is defined as donor plasma containing 
isohemagglutunin to antigens on recipient RBC causing severe 
morbidity and mortality. This is especially true for those transfusions of 
group O plasma or platelets to group A, B or AB recipients.  
Passively acquired antibodies are detectable in recipients only 
when the donor antibody titres are high. In these cases the transfusion 
reactions ensue when the plasma contains a high titre antibody, when 
large volume of plasma are transfused or when small children and 
infants received transfusion. Most of the hospital services do not 
 24
routinely measure isohemagglutunin titres (IgM or IgG) before 
transfusing ABO mismatched plasma, although some recommend this. 
A policy was instituted to test anti A, anti B, anti AB titres of all group 
O Single Donor Platelets  before transfusion to group A patients. If 
IgM> 1: 64 and or IgG is > 1:256, the platelet product is not transfused 
out of group.27 
3.13 Leukemia and Alloimmunisation 
Alloimmunisation represents the major complication of platelet 
transfusion therapy for patients with acute leukemia.28 Platelet 
refractoriness defined as two or more consecutive uncorrected post 
transfusion platelet count increments of less than 4,000 per ml. Patients 
who become alloimmunized following induction will continue to require 
HLA matched platelets. However, patients who do not become 
immunized during induction can easily and repeatedly be transfused 
with random donor platelets and can therefore be given subsequent 
prophylactic transfusions liberally without concern for the induction of 
alloimmunisation.28 
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3.14 Corrected count increment (CCI) 
The corrected count increment has been used as a surrogate 
measure for bleeding in platelet dose studies and also for platelet 
transfusion triggers studies. 
 
 
CCI may not be a valid and reproducible surrogate marker as it 
depends upon (a) BSA – Calculation of BSA is variable as per the 
formula used. (b) Total No. of Platelets in the Platelet product 
transfused.25 
Hematology Laboratory using electronic counter were not 
designed to accurately count cells in platelets rich plasma. The potential 
sources of variation in results includes     
1. Method of taking the sample  
2. Type of test tube that the sample is placed (plastic or glass) 
3. Duration of time that the sample sits before being counted 
4. The accuracy of making the dilution 
5. The instrument on which the counting is being performed 
      Platelet count increment (Post count – Pre count) X BSA 
CCI = 
    No. Of Platelets in the transfused products (X 1011) 
 26
There are many studies which showed that there is significant 
variability in counting depending on the instrument that is being used. 
BEST study demonstrated the variability in platelet counts performed on 
samples of platelet rich plasma in eight different laboratories in five 
different countries. 20 – 60% of patients requiring regular platelet 
transfusions failed to achieve adequate post transfusion increments and 
are considered to be refractory to platelet transfusion.29 The factors 
influencing CCI are 1. Splenectomy, 2. Bone marrow transplantation,  
3. Concurrent IV administration of Amphotericin B., 4. Palpable Spleen, 
5. Temperature.28 Amphotericin B also binds to the sterol moiety of 
membrane to produce increased permeability and lysis of red cells.28 
3.15 Guidelines for platelet transfusion in infants 
The goal of most platelet transfusion is to raise the blood platelet 
count to greater than 50 X 109/L. Transfusion of 10ml/Kg of platelet 
concentrate provides approximately 10X109 platelets. Considering the 
blood volume of an infant is 70ml / kg body weight and the recovery of 
transfused platelets to be 50%, a platelet dose of 10ml / kg will increase 
the immediate post transfusion platelet count by 100 -150 X 109/L.30 
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3.16 Factors that affect the response to platelet transfusion10 
Table 2 Factors that affect the response to platelet transfusion10 
Clinical Patient Blood bank 
Fever Alloimmunization  ABO mismatch 
Sepsis Disease Storage time 
Splenomegaly Drugs  
Bleeding BMT recipient   
DIC   
Platelet count   
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4. MATERIALS AND METHODS 
4.1 Study Design and Place 
• An Observational Study conducted in the Department of 
hematology, Institute of Child Health during the period 2007 
– 2008. The study population included children diagnosed as 
acute leukemia in the age group  1 – 12 years. 
4.2 Inclusion Criteria  
• All acute leukemic Children, 1 – 12, years both male and 
female. 
• Children diagnosed as acute lymphoblastic leukemia and 
acute myeloid luekemia. 
• All acute leukemic Children requiring transfusion support. 
• Both treated and follow up children. 
4.3 Exclusion Criteria  
• Leukemic children below 1 year and above 12 years. 
• Lymphoma evolving to leukemic phase. 
• Juvenile myelomonocytic leukemia. 
• Not willing to participate in this study. 
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4.4 Variables Studied 
• Age, Sex, Weight 
• Hemoglobin Level 
• Platelet Count 
• Hematocrit 
4.5 Sample Size 
Sample Size is calculated by the formula N =  Z2  P (1-P) / d2 
Where N = Sample Size 
Z = Z statistic for a level of confidence. 
P = expected  prevalence  or proportion  
d = Precision 
Z statistic (z): CI-95%, Z value is 1.96 
N = (1.96)2 x 0.1 (1-0.1) / (0.05)2 = 135 
(This is for 10% Prevalence & for  20 -  50% Prevalence it is 245) 
So the total sample taken for the study is 250 and in this  the 
transfusion of each unit is taken as one sampling unit.  
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4.6 Components prepared 
The components used in this study were platelets and packed red 
cells and were prepared as follows: 
 
 
 
 
 
The red cells were stored at 2-6°C (shelf life 35 days) and the 
platelets were stored at 20-24°C (shelf life 5 days) under constant gentle 
agitation. 
The platelets were neither leukoreduced nor irradiated. No 
apheresis platelets were used. 
The transfusion was given depending upon the clinical sign of 
bleeding and the hemoglobin estimation. The following data have been 
documented in this study for analysis.   
Anti coagulated whole 
blood 
PRBC Platelet Rich 
Plasma 
Soft  Centrifugation 
Hard Centrifugation 
Plasma Platelet 
Concentrate 
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The hematology analyser used in this study was Sysmex4000 
working on the principle of Impedance .The pre and post transfusion 
hemoglobin and platelet count were estimated 24 hours after the 
transfusion. 
Hemoglobin content of the RBC and platelets were estimated as a 
quality measure once in a month randomly. The hematology analyser 
used was calibrated once in three months using known samples.   
4.7 Variables 
  Before transfusion the following data were documented and the 
variables used in the study are 
• Pre Hemoglobin count 
• Pre platelet count 
• No of units of RBC and platelets transfused 
• Post hemoglobin count after 24 hrs of transfusion 
• Post platelet count after 24 hrs of transfusion 
• Clinical signs of bleeding and platelet count. 
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5. RESULTS 
Two hundred and fifty episodes of transfusion given to 30 
leukuemic children were analysed . The data is analysed as follows: 
5.1 Demographic details 
5.2 Clinical features 
5.3 Analysis of transfusion 
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5.1 (a) Demographic details 
Table 3 Age & Sex distribution 
ALL AML 
Age  (in years) 
M F M F 
1-3 years 5 2 1 0 
4-6 5 1 3 0 
7-9 2 1 2 0 
10-12 3 3 2 0 
Total 15 7 8 0 
 
0
2
4
6
8
10
12
14
16
M F M F
ALL AML
1 - 3
4 - 6
7 - 9
10 - 12
Total
 
From the above details, 76.67% were males and 23.33 were 
females. In leukemia 73.33% were acute lymphoblastic leukemia and 
26.67 were acute myeloid leukemia.  
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5.1 (b) Blood group distributions 
Table 4 Blood group distribution 
Blood Group Number of children 
A+ 2 
A1+ 5 
AB+ 2 
B+ 9 
O+ 12 
Total 30 
 
2
5
2
9
12
A+
A1+
AB+
B+
O+
 
Here 40% of the leukemic children belonged to O group which is 
similar to the general distribution. It is unusual that none of them were 
Rh negative whereas in the general population it is 15%. 
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5.2 Clinical Features 
The Leukemic children presented with the following major 
clinical features  
1. Fever 
2. Hepatomegaly 
3. Splenomegaly 
4. Lymphadenopathy 
5. Anemia  
6. Bleeding 
 36
Table 5 Clinical features 
n=30 
Clinical Features ALL 
n=22 
AML 
n=8 
Fever 2(9.1%) 0 
Hepatomegaly 16(72.7%) 5(62.5%) 
Splenomegaly 11(50%) 3(37.5%) 
Lymphadenopathy 6(27.8%) 6(75%) 
Bleeding 4(18.2%) 4(50%) 
 
0
2
4
6
8
10
12
14
16
18
ALL (n = 22) AML (n = 8)
n = 30
Fever
Hepatomegaly
Splenomegaly
Lymphadenopathy
Bleeding
 
Hepatomegaly  and Splenomegaly were  common among the 
clinical features and 22% of the patients presented with bleeding. 
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Table 6 Presence of Anemia 
Hb% in grams No. Of Children 
< 7 15 
7.1 to 10 10 
10 to 12 5 
 
15
10
5
< 7
7.1 to 10
10 to 12
 
At the time of presentation 5 of the children had hemoglobin  
> 10gms %. 15 children had hemoglobin < 7gms % and among them  
2 presented with bleeding and 10 children had hemoglobin between 7.1 
to 10gms % and among them 4 presented with bleeding. Cause and 
effect of anemia with bleeding could not be ascertained from their 
presentation. 
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5.3 Analysis of Transfusions 
30 Leukemic children received 250 transfusions. 52 of them were 
packed red blood cells. 198 of them were platelets. Of this 47 platelet 
transfusions were single unit, 33 received double units and 16 received 
more than 3 units at a time. Pre Hemoglobin and post Hemoglobin 
estimation and the pre platelet and post platelet count were done after 24 
hours of transfusion. 
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Algorithm of Transfusion episodes 
 
 
 
 
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
       
                     
 
 
 
 
 
 
 
 
      
Components Transfused 
Total no. of transfusion episodes : 250 units 
30 patients (23 males, 7 females) 
Packed red blood 
cells
Random donor 
platelets
No of transfusion 
episodes 52 
No of transfusion 
episodes 198 
Single unit
47
Double unit
47
More than 2 units
15 
26 patients
Mean post transfusion 
increment 1.12 grams % 
 
(SD +/- 0.48) 
Mean post 
transfusion 
increment 
Mean post 
transfusion 
increment 
Mean post 
transfusion 
increment 
4900/µl 
 
(SD+/-1943) 
9700/µl 
 
(SD+/-3596)
11200/µl 
 
(SD+/-8925)
18 patients 20 patients 11 patients 
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5.3 (a) Clinical Factors Influencing Platelet Count 
Table 7 Bleeding Vs Platelet count 
Bleeding 
Platelet Count  
< 5000 / µl 
Platelet Count  
> 5000 / µl 
Present 4 4 
Absent 1 21 
 
Odds ratio = 21(p < 0.05)* Bleeding is definitely associated with 
thrombocytopenia.  
Table 8 Splenomegaly Vs Platelet Count 
Splenomegaly 
Platelet Count  
< 5000 / µl 
Platelet Count  
> 5000 / µl 
Present 2 12 
Absent 1 15 
 
Odds ratio = 2.5 (p<0.05)* Presence of Splenomegaly is also 
connected with low platelet count. 
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Table 9 Fever Vs Platelet Count 
Fever 
Platelet Count  
< 5000 / µl 
Platelet Count  
> 5000 / µl 
Present 1 1 
Absent 4 24 
 
Odds ratio = 6 (p<0.05)* Presence of fever also contributes to 
thrombocytopenia. 
Table 10 Distribution of platelet count in children with bleeding 
Platelet Count No. of children with bleeding 
< 5000/µl 4 
> 5000/µl 4 
 
8 children presented with bleeding and 50 % had platelet count  
< 5000/µl and 50 % had platelet count > 5000/µl. 
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Table 11 Distribution of platelet count in children without bleeding 
Platelet Count in µl No. of children without bleeding 
0-5000 0 
5,000-10,000 8 
10,000 – 15,000 3 
15,000 - 20,000 0 
20,000 – 25,000 1 
25,000 – 30,000 1 
30,000 – 35,000 0 
35,000 – 40,000 2 
40,000 – 45,000 0 
45,000 – 50,000 0 
> 50,000 5 
 
Here 20 children presented without bleeding as shown in the 
above table. 
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Statistically there is no correlation with the platelet count between 
the number of children with and without bleeding  
5.3 (b) Analysis of RBC transfusions 
52 packed red cell transfusions were given. In order to find the 
post hemoglobin level rise, the following analysis was done and their 
analysis is as follows: 
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Table 12 Analysis of RBC transfusions 
Paired samples t-test n = 52 
 Pre transfusion Post transfusion P 
Sample size 52 52 P < 0.0001 
Mean of the Hb 
level in gms % 
6.7346 7.8558
95% CI for the  
mean 
6.2163 to 7.2529 7.3471 to 8.3645
Variance 3.4662 3.3386
Mean difference 1.1212
Test statistic t 16.846
Degrees of Freedom
(DF) 
51
 
In the above analysis it is found that there is a mean difference of 
1.1212 grams % and for 95% CI for the mean p < 0.0001, the post 
transfusion rise in Hb is significant. 
Histogram of differences 
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5.3 (c)Analysis of Platelet Transfusions 
Out of 198 platelet transfusion analysis about the Pre & Post 
platelet count were done for single unit, double unit & for 3 & 4 units 
separately as follows: 
Single unit platelets transfusion   = 47 
Double unit platelets transfusion  = 51 
 More than 2 units platelets transfusion = 15 
5.3 (d) Single Unit Platelet Transfusion 
After giving 47 single unit platelet transfusion to 18 leukemic 
children the following analysis were done to find a rise in post platelet 
count increment. 
 46
Table 13 Analysis of single unit platelet transfusion 
Paired samples t-test   n = 47 
  Pre transfusion Post transfusion P 
Sample size 47 47 P < 0.0001
Mean of the platelet 
count in 103 µl/l  
39.3745 44.3553 
95% CI for the 
mean 
30.4899 to 48.2590 35.3566 to 53.3541 
Variance 915.6493 939.3299 
Mean difference 4.9809  
Test statistic t 17.572  
Degrees of Freedom
 (DF) 
46  
 
In the above analysis it is found that there is a mean difference of 
4.9809X103  µl / l  from the pre and post  platelet single unit transfusion. 
For 95% CI for the mean, the P < 0.0001 and so the rise in  post 
transfusion platelet count is significant. 
Histogram Of Difference 
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5.3 (e) Double units platelets transfusion 
51 double units were given and the following analysis done to 
find out the post platelet count increment 
Table 14 Analysis of Double unit’s platelets transfusion 
Paired sample t-test n = 51 
  Pre transfusion Post transfusion P 
Sample size 51 51 P < 0.0001
Mean of the platelet 
count in 103 µl/l  
35.5843 45.3784 
95% CI for the mean 27.4889 to 43.6798 36.9598 to 53.7971 
Variance 828.4809 895.9477 
Mean difference 9.7941  
Test statistic t 19.448  
Degrees of Freedom  
(DF) 
50  
 
In the above analysis it is found that there is a mean difference of 
9.7941X103 µl/l platelets between the pre and post platelets double units 
transfusion. For 95 % CI of the mean, P < 0.0001 and so the rise in 
platelet count is significant 
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Histogram Of Differences 
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5.3 (f) Three & Four unit platelet Transfusion 
Here the analyses were done for patients receiving more than 2 
units of platelets. It was found that 11 of them received 3 units and four 
of them received 4 units at a time respectively. So these 15 transfusions 
were analyzed together.  
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Table 15 Analysis of Three & Four unit platelet Transfusion 
Paired sample t-tests n=15 
 Pre transfusion Post transfusion P 
Sample size 15 15 P = 0.0002
Mean of the platelet 
count in 103 µl/l 
27.7133 38.9600 
95% CI for the  
mean 
16.9953 to 38.4314 27.0850 to 50.8350 
Variance 374.5898 459.8240 
Mean difference 11.2467  
Test statistic t 4.880  
Degrees of Freedom  
(DF) 
14  
 
In the above analysis it is found that there was a mean difference 
11.2467X103 µl/l Platelets between the pre and post platelets transfusion 
from those who received more than 2 units. For 95% CI for the mean,  
P < 0.00001 and the rise in platelet count is significant. 
Histogram Of Differences 
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6. DISCUSSION 
Hemato-oncology services require many transfusions for a 
prolonged period. Profound anemia can alter hemostasis and thus should 
be avoided in patients with thrombocytopenia.10 Kathryn E. Webert et al 
hypothesized that maintaining the hemoglobin concentration of a patient 
with thrombocytopenia at a higher level may contribute to improved 
homeostasis. In this study, they found that once the patients’ 
hemoglobin level reached the targeted threshold, there were no 
differences between groups with respect to number of RBC or platelet 
transfusion.16 Normal platelet survival is approximately nine days. 
Hansor SR et al suggested that patients under going induction 
chemotherapy for leukemia often require platelet transfusion at least 
every three days. E. Pattern and Visania et al published that acute 
leukemic patients receive on average 80 – 110 units of platelets and  
20 – 40 units of red cells.20   
In this study, 50 leukemic children were admitted and among 
them only 30 (60%) children needed transfusion support.  
In the present study, out of 250 transfusions given to 30 leukemic 
children, 55 were packed red cells (mean 1.9 transfusions) and the rest 
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198 were random donor platelets (mean 2.3). Of 52 packed red cell 
transfusion episodes given to 22 patients, five of them received more 
than four units of red cells during the study period. The mean 
haemoglobin increment for single unit of packed red cell transfusion 
was 1.12 gms%. 15 children had haemoglobin <7 gms%, 10 of them had 
haemoglobin level between 7.1 to 10 gms% and 5 of them presented 
>10 gms%. Of this 15 children, only two presented with bleeding, but 
among 10 children who had haemoglobin level between 7.1 to  
10 gms%, four of them presented with bleeding. Cause and effect of 
anemia with bleeding could not be ascertain from their presentation. 
There was no optimal RBC transfusion trigger followed. Out of 198 
random donor platelets given to 28 leukemic children, 17 of them 
received less than 5 units, 8 of them received 5 to 10 units and 3 of them 
received more than 20 units.  The most common component used in the 
study was platelets and the number of platelets provided per transfusion 
was not ascertained.   
The Number of platelet transfusions has increased more than 
transfusion of other blood components in leukemic patients primarily 
because of more aggressive chemotherapies producing acute and 
prolonged thrombocytopenia. A prophylactic platelet transfusion 
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approach can prevent bleeding, as opposed to therapeutic approach, in 
which platelet transfusion is given after a certain degree of hemorrhage 
has occurred. High et al in 21 patients with acute leukemia found that 
fever preceded hemorrhage in 10 of the 13 patients who experienced 
bleeding23. In the present study, 2 out of 30 patients (6.3%) had fever 
and among these two, one had bleeding episode with a platelet count of 
<5000/µl. 
The most controversial aspect of platelet transfusion therapy 
involves the delineation of the level at which prophylactic platelet 
transfusion should be administered. Guidelines for the use of 
prophylactic platelet transfusion are primarily based on clinical 
experience. In pediatric oncology patients, there are two contrasting 
points of view. One group tells that the patients should be transfused 
whenever platelet count falls below 20000/µl, where as the other groups 
believes that patient should be transfused only when frank bleeding 
occurs.   
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Table -16 Summary of Platelet Transfusion Trigger Trials 
Study Year N-type Patients 
Bayer wl et al 1992 31 Malignancy 
Gumur  et al 1992 105 Acute Leukemia 
Heckman et al 1997 78 Acute Leukemia 
Rebulla et al 1997 255 Acute Leukemia 
Wandt et al 1998 105 Acute Myeloid Leukemia 
 
Bayer WL et al found that patients with platelet counts less than 
6000/µl received prophylactic transfusion, where as those with counts 
greater than 20000 / µl where transfused only for major bleeding. They 
concluded that prophylactic level of 5000/µl was safe in the absence of 
fever or bleeding. Gumer et al, Heckman et al, Rebulla et al have 
compared the bleeding risk and platelet transfusion needs of groups of 
thrombocytopenic patients’ who received platelets either at  the 
10000/µl  or 20000/µl threshold. They found that there is no difference 
in hemorrhagic morbidity and mortality rates when the lower platelet 
transfusion trigger values are used.13 One major reason for variable 
practice is based on the need to modify threshold numbers when 
thrombocytopenia is combined with other complications that increase 
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the risk of bleeding. In the present study no transfusion trigger was 
followed. Platelets were transfused to 28 Leukemic children based on 
their platelet count and bleeding episodes. Out of 198 transfusion 
episodes given, 8 patients (28.5%) presented with bleeding.  In this 
study 4 of them presented with a platelet count <5000/µl. In this study 
the clinical signs presented by the leukemic children – bleeding, 
splenomegaly and fever were analyzed with the platelet count below and 
above 5000 per µl and the odds ratio calculated and were found to be 
significant as shown in table 7,8 & 9. The distribution of platelet count 
children with bleeding and without bleeding were analysed as shown in 
table 10 & 11. Bleeding was significantly present with platelet count 
<5000/µl also. 
  The problems that might have been faced by the physician to 
decide on an optimal prophylactic threshold could be  
(1) Serious hemorrhage was rare at lower platelet numbers. 
(2) Presence of minor clinical bleeding. 
(3) Accuracy of platelet count when very low platelet numbers 
found in severely thrombocytopenic patients.  In clinical 
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practice it is difficult to evaluate the efficiency of platelet 
transfusion due to the fact that   
(a) Severe bleeding due to thrombocytopenia alone is rare.   
(b) Mortality due to hemorrhage in thrombocytopenia is not 
common. The bleeding time is not helpful in 
determining the effectiveness of platelet transfusion. 
Some times platelet count does not increase to the 
expected level after platelet transfusion.  
Janice P Dutcher et al studied in 114 patients with acute 
lymphoblastic leukemia who received multiple course of chemotherapy 
and several platelet transfusions and found that 92% of the patients 
never become  alloimmunized and responded to random donor platelets. 
Those who remain alloimmunized tended to remain alloimmunized for 
their entire clinical course. There was no difference in age or sex 
between groups and prognostic factors predicting alloimmunization . 
Dutcher in his previous studies also found that there is no dose response 
relationship between the development of alloimmunization and the 
number of units of platelets given during induction.31 In the present 
study there was platelet increment in all the transfusion episodes and 
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there was no refractoriness. The mean increment for single unit 
transfusion (2.6) is 4900/µl and for double unit transfusion (2.6) is 
9700/µl and for more than 2 units (1.36) is 11200/µl and the standard 
deviation is +/- 1943,  3596 and 8925 respectively. 
Jeffrey McCullough in 2000 published the data of Williams et al 
and said that the use of platelet transfusion is associated with increased 
risk of viral and bacterial infection and alloimmunisation. In the present 
study of thirty leukemic children all were negative for transfusion 
transmissible infections.  He also found that transfusion reaction occur 
after 5% to 30% of platelet transfusion and the most common adverse 
reaction is febrile non hemolytic transfusion reaction which is caused by 
the patients leukocyte antibodies reacting with leucocytes in the 
transfused components. In the present study out of 28 children who 
received platelet transfusion two of them experienced febrile non-
hemolytic transfusion reaction. 
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Table 16 Studies addressing the issue of optimal platelet dose25 
Study Year Patients N Dosage of platelets 
Noral et al 1998 AML 69 Medium Dose = 4- 6 x1011  
High Dose = 6 – 8x1011 
Very High Dose = >8x1011 
Goodnough 
et al 
2001 Chemotherapy 
induced 
thrombocytopenia
120 Medium Dose = 3.4- x1011  
High Dose = 5.7 x1011 
Very High Dose = 11x1011 
Klumpp  
et al 
1993 Human 
progenitor cell 
transplant 
46 High Dose =  5 x1011 
Low Dose =   3x1011 
TinMouth 
et al 
2005 ALL / AML 111 High Dose = 5 WB 
derived   platelets  poole 
Low Dose =   3 WB derived 
 platelets pooled 
Sensebe’  
et al 
2005 Acute Leukemia   96 Single Dose = .5x1011    
                              Pl / 10kg 
Double Dose = Twice this 
amount 
 
In the above studies the transfusion of high dose platelets is 
associated with the statistically significant increase in transfusion 
interval and the post transfusion platelet increment. None of the studies 
adequately addressed the question of optimal dose for prophylactic 
platelet transfusion.25     
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7. SUMMARY 
¾ All leukemic children included in this study were given 
transfusion and all of them who were transfused showed 
significant clinical improvement showing that there is a need 
for transfusion support in this group. 
¾ Most common blood component used in this study was 
platelets (79%) and the remaining were red cells (21%). 
¾ There was a mean hemoglobin rise of 1.12g% after 
transfusion of one unit of red cells. 
¾ The platelet increment were as follows: 
For single unit – 4.98 x 103  / µl 
For double unit – 9.74 x 103 / µl 
For more than 2 units – 11.2 x 103 / µl 
Platelet count increment was present in all transfusion 
episodes and there was no refractoriness.  
7.14% of leukemic children experienced febrile non-
hemolytic transfusion reaction. 
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  All children were  negative  for transfusion transmissible 
infections at the end of the study. 
¾ 50% of the children who presented with bleeding had platelet 
count < 5000 per microlitre. 
¾ Transfusions were based purely on clinical signs and no 
transfusion trigger was followed. 
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8. CONCLUSION 
 There is a definite clinical improvement with transfusion of blood 
components in leukemic children and also there is no refractoriness to 
the number of units transfused. The decision to transfuse blood 
components can be followed based on the clinical signs and symptoms. 
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S.NO PRE HB
NO OF 
UNITS
POST 
HB S.NO PRE UNIT POST
1 GANI 1806/08 3 M 13 ALL AB + 2 5 7 1 1 2 2 2 1. ALL 1 3.1 1 3.9 3 80x103 1 89X103
2 4.1 1 5.4 4 88x103 2 100X103
5 120x103 2 131X103
2 HARI ROSHAN 436/08 2 M 11 ALL A1 + 2 4 6 1 1 2 2 2 2. ALL 1 4.8 1 6.1 3 14x103 3 29x103
2 5.2 1 7.8 4 29x103 4 36x103
5 36x103 5 42X103
3 PRASANTH 331/08 12 M 30 AML A + 4 29 33 2 2 2 2 2 3. AML 1 5 1 6.8 5 4x103 2 9X103
2 6.8 1 7.2 6 8x103 2 19X103
3 7.1 1 8 7 19x103 4 32X103
4 7.2 1 8.2 8 32x103 3 17X103
9 17x103 1 20X103
10 20x103 3 28X103
11 28x103 1 31X103
12 31x103 1 36X103
13 36x103 1 39X103
14 39x103 2 48X103
15 48x103 2 59X103
16 59x103 1 63X103
17 63x103 1 65X103
18 65x103 2 71X103
19 71x103 3 84x103
4 SURYA 1737/07 2 M 12 AML O + - 2 2 1 1 2 1 2 4.AML 1 40x103 2 19X103
5 PRIYADARSHINI 359/08 3.5 F 13 ALL B + 4 5 9 2 2 2 2 2 5.ALL 1 5.2 1 7.1 1 40x103 2 57X103
2 7.1 1 7.9 2 57x103 2 67X103
3 6.1 1 7.2 3 67x103 1 75X103
4 7.2 1 8.8
6 NIROSHA 514/08 10 F 25 ALL B + 1 3 4 2 2 1 2 2 6. ALL 1 5.2 1 7.1 1 26x103 3 56X103
7 SURYA 1026/08 11 M 28 ALL B + 1 - 1 1 1 2 1 2 7.ALL 1 6.8 1 7.4
8 SHARUKA 1552/07 7 M 22 ALL B + 2 2 4 2 2 2 1 2 8. ALL 1 7 1 8.2 1 120x103 1 125X103
2 7.8 1 8 2 80x103 1 85X103
9 JOSHUA 846/03 11 M 28 ALL O + - 3 3 1 1 2 1 2 9. ALL 1 10x103 3 25X103
10 VIJAY 220/08 5 M 18 ALL O + 1 2 3 1 2 2 2 2 10. ALL 1 6.8 1 7.2 1 10x103 2 18X103
11 LATHA 1623/07 2 F 12 ALL B + 1 1 2 1 1 2 2 2 11. ALL 1 5.2 1 6.4 1 11x103 1 15X103
12 KARTHIKA 711/08 12 F 31 ALL B + 1 - 1 2 2 2 2 2 12. ALL 1 6.2 1 7.8
13 VENKATESH 273/08 3.5 M 12 ALL A1 + 4 7 11 1 1 1 2 2 13. ALL 1 7.2 1 8 1 9x103 3 20X103
2 8 1 9.9 2 20x103 1 24X103
3 9.7 1 10.8 3 4x103 1 10X103
4 8.9 1 10.1 4 10x103 1 16X103
14 ABINASH 286/08 8 M 22 AML O + 4 20 24 1 1 1 1 2 14. AML 1 8.6 1 10.8 1 2x103 1 7.2X103
2 10.8 1 11.9 2 7.2x103 1 13.3X103
3 4.9 1 5.4 3 13.3x103 1 19.8X103
4 5.4 1 7 4 19.8x103 1 22.4X103
5 22.4x103 2 31.3X103
6 31.3x103 2 39X103
7 39x103 4 52X103
8 52x103 1 59.3X103
9 59.3x103 1 62X103
10 62x103 1 68.7X103
11 68.7x103 3 82.4X103
12 70x103 1 74X103
13 72x103 1 76X103
15 PRADEEP 873/08 4 M 15 AML O + 1 6 7 1 1 1 2 2 15. AML 1 2.1 1 3.4 1 75x103 2 87X103
2 87x103 2 93X103
3 93x103 2 100X103
16 ELUMALAI 609131 6 M 18 AML B + 3 7 10 1 2 1 1 2 16. AML 1 7.8 1 9.2 1 5x103 1 8X103
2 9 1 9.8 2 8x103 1 10X103
3 9.8 1 10.5 3 10x103 1 16X103
4 16x103 1 20X103
5 20x103 2 32X103
6 32x103 1 38X103
7 38x103 1 46x103
17 RAHUL 605432 4 M 16 AML B + - 2 2 2 2 1 2 2 17. AML 1 90x103 1 100X103
18 MONICA 627/08 12 F 30 ALL O + - 1 1 1 2 1 2 2 18. ALL 1 37x103 1 41X103
19 SAI SIDDARTH 1540/07 9 M 22 AML O + 1 28 29 2 2 1 1 2 19. AML 1 7 1 7.8 1 10x103 2 18X103
2 18x103 2 26X103
3 26x103 2 31X103
4 31x103 2 39X103
5 39x103 2 47X103
6 10x103 2 20X103
7 20x103 1 24X103
8 24x103 4 37X103
9 37x103 2 44X103
10 44x103 2 54X103
11 54x103 2 61X103
12 61x103 1 65X103
13 65x103 2 76X103
14 76x103 1 81X103
15 81x103 1 86X103
20 NANDA KUMAR 764/08 4.5 M 16 ALL O + 2 6 8 1 2 1 2 2 20. ALL 1 7.6 1 8.8 1 10x103 2 18X103
2 8 1 9.2 2 18x103 2 29X103
3 10x103 1 16X103
4 16x103 1 24X103
21 FARHUL RAHUMAN 733/08 3.5 M 15 ALL A1 + 1 8 9 1 1 2 2 2 21. ALL 1 3 1 4.1 1 4x103 1 11X103
2 11x103 2 18X103
3 15x103 2 24X103
4 25x103 2 31X103
5 30x103 1 36X103
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